SCHEMBL1627210

SCHEMBL1627210

CC(C)(C)n1ncc(Cl)c(Cl)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 10/20 0.50
HTT P42858 10/20 0.50
ALDH1A1 P00352 7/20 0.50
NPC1 O15118 6/20 0.50
MITF O75030 3/20 0.50
RAB9A P51151 8/20 0.48
LMNA P02545 5/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
GPR35 Q9HC97 2/20 0.48
GALR3 O60755 1/20 0.48
NR2F2 P24468 1/20 0.48
GPR183 P32249 1/20 0.48
HPGD P15428 2/20 0.46
ATM Q13315 1/20 0.46
NPSR1 Q6W5P4 6/20 0.45
MAPT P10636 3/20 0.44
PAX8 Q06710 3/20 0.44
S1PR4 O95977 3/20 0.44
S1PR1 P21453 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3845405 0.82 SMN1; SMN2 (0.43) SMN1; SMN2HTTALDH1A1NPC1MITF
SCHEMBL17738012 0.82 SMN1; SMN2 (0.50) SMN1; SMN2HTTALDH1A1NPC1MITF
SCHEMBL9372342 0.82 HTT (0.49) SMN1; SMN2HTTALDH1A1NPC1MITF
SCHEMBL19738690 0.82 HTT (0.49) SMN1; SMN2HTTALDH1A1NPC1MITF
SCHEMBL27619400 0.81 SMN1; SMN2 (0.46) SMN1; SMN2HTTALDH1A1NPC1MITF
SCHEMBL11272569 0.81 SMN1; SMN2 (0.46) SMN1; SMN2HTTALDH1A1NPC1MITF
SCHEMBL1627207 0.81 SMN1; SMN2 (0.46) SMN1; SMN2HTTALDH1A1NPC1MITF
SCHEMBL3847199 0.81 SMN1; SMN2 (0.46) SMN1; SMN2HTTALDH1A1NPC1MITF
SCHEMBL8545976 0.79 SMN1; SMN2 (0.39) SMN1; SMN2HTTALDH1A1NPC1MITF
SCHEMBL19738637 0.79 HTT (0.47) SMN1; SMN2HTTALDH1A1NPC1MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0169375-B1 PROCESS FOR PRODUCING 2-TERT.-BUTYL-4,5-DICHLORO-3(2H)-PYRIDAZINONE NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1989-12-20 EP claimed
EP-0169375-A2 Process for producing 2-tert.-butyl-4,5-dichloro-3(2H)-pyridazinone NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1986-01-29 EP claimed
JP-5294942-A None JP disclosed
JP-1213280-A None JP disclosed
JP-61010560-A None JP disclosed
JP-61010561-A None JP disclosed
JP-61109777-A None JP disclosed
JP-61112058-A None JP disclosed
JP-61097270-A None JP disclosed
US-20250242063-A1 METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF LANTHEUS MEDICAL IMAGING, INC. (US) 2025-07-31 US disclosed
CN-120136791-A Pyridaben intermediate II New synthesis process of chloropyridazinone 河北优农派生物科技有限公司 2025-06-13 CN disclosed
JP-S6197270-A PRODUCTION OF PYRIDAZINONE DERIVATIVE NISSAN CHEM IND LTD 1986-05-15 JP disclosed
EP-0169375-A2 Process for producing 2-tert.-butyl-4,5-dichloro-3(2H)-pyridazinone NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1986-01-29 EP disclosed
EP-0169375-A2 Process for producing 2-tert.-butyl-4,5-dichloro-3(2H)-pyridazinone NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1986-01-29 EP disclosed
EP-0169375-A2 Process for producing 2-tert.-butyl-4,5-dichloro-3(2H)-pyridazinone NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1986-01-29 EP disclosed
JP-S6110560-A PREPARATION OF 2-TERTIARY-BUTYL-4,5-DICHLORO-3(2H)-PYRIDAZINONE NISSAN CHEM IND LTD 1986-01-18 JP disclosed
JP-S6110561-A PREPARATION OF 2-TERTIARY-BUTYL-4,5-DICHLORO-3(2H)-PYRIDAZINONE NISSAN CHEM IND LTD 1986-01-18 JP disclosed
EP-0134439-A1 Pyridazinone derivatives, preparation thereof and insecticidal, acaricidal, fungicidal compositions NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1985-03-20 EP disclosed
US-4366155-A 1-Benzoyl-3-(6-oxopyridazinyl)ureas, compositions, and insecticidal method ELI LILLY AND COMPANY (US) 1982-12-28 US disclosed
EP-0063413-A1 1-Benzoyl-3-(heterocyclic)ureas, compositions, and insecticidal method ELI LILLY AND COMPANY (US) 1982-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250242063-A1 METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF TNNI3, FABP3, MPI SMN1; SMN2 2628/4885HTT 4436/4885ALDH1A1 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.